Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline

Brain

Volumn 140, Issue 8, 2017, Pages 2112-2119

  Ayton, Scott ^a   Fazlollahi, Amir ^b,c   Bourgeat, Pierrick ^b,c   Raniga, Parnesh ^b   Ng, Amanda ^a   Lim, Yen Ying ^a   Diouf, Ibrahima ^a,b   Farquharson, Shawna ^a   Fripp, Jurgen ^b,c   Ames, David ^a,d   Doecke, James ^b,c   Desmond, Patricia ^a   Ordidge, Roger ^a   Masters, Colin L ^a,c   Rowe, Christopher C ^a,e   Maruff, Paul ^a,f   Villemagne, Victor L ^a,e   Salvado, Olivier ^b,c   Bush, Ashley I ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSIRO   (Australia)

^c Academic Centre for Community Mental Health   (Australia)

^d NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^e AUSTIN HEALTH   (Australia)

^f Scientific Division   (Australia)

Author keywords

Alzheimer's; cognitive decline; iron; MRI; Quantitative Susceptibility Mapping

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; IRON; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; AUSTRALIAN; BRAIN MAPPING; BRAIN TISSUE; CASE CONTROL STUDY; CLINICAL ARTICLE; COGNITION; COGNITIVE FUNCTION TEST; COHORT ANALYSIS; CONTROLLED STUDY; DATA COLLECTION METHOD; DIAGNOSTIC TEST ACCURACY STUDY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMAN; LANGUAGE TEST; MALE; MEASUREMENT ERROR; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; QUANTITATIVE SUSCEPTIBILITY MAPPING; SUSCEPTIBILITY WEIGHTED IMAGING; TEMPORAL LOBE; TISSUE LEVEL; COGNITIVE DYSFUNCTION; COMPLICATION; DIAGNOSTIC IMAGING; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; COGNITIVE DYSFUNCTION; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; TEMPORAL LOBE;

EID: 85028318324     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awx137     Document Type: Article

References (48)

1. Acosta-Cabronero J, Betts MJ, Cardenas-Blanco A, Yang S, Nestor PJ. In vivo MRI mapping of brain iron deposition across the adult lifespan. J Neurosci 2016; 36: 364-74.
2. Acosta-Cabronero J, Williams GB, Cardenas-Blanco A, Arnold RJ, Lupson V, Nestor PJ. In vivo Quantitative Susceptibility Mapping (QSM) in Alzheimer's disease. PLoS One 2013; 8: e81093.
3. Ayton S, Faux NG, Bush AI. Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-epsilon4 carriers. JAMA Neurol 2017; 74: 122-5.
4. Ayton S, Faux NG, Bush AI; Alzheimer's Disease Neuroimaging Initiative. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat Commun 2015; 6: 6760.
5. Ayton S, Lei P, Bush AI. Biometals and their therapeutic implications in Alzheimer's disease. Neurotherapeutics 2014; 12: 109-20.
6. Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging 2015; 36: S159-66.
7. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991; 337: 1304-8.
8. Daugherty AM, Haacke EM, Raz N. Striatal iron content predicts its shrinkage and changes in verbal working memory after two years in healthy adults. J Neurosci 2015; 35: 6731-43.
9. Daugherty AM, Raz N. Accumulation of iron in the putamen predicts its shrinkage in healthy older adults: a multi-occasion longitudinal study. Neuroimage 2016; 128: 11-20.
10. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009; 21: 672-87.
11. Fazlollahi A, Ayton S, Bourgeat P, Raniga P, Ng A, Fripp J, et al. A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping. In: IEEE International Symposium on Biomedical Imaging, Melbourne; 2017: 97-100.
12. Ghadery C, Pirpamer L, Hofer E, Langkammer C, Petrovic K, Loitfelder M, et al. R2 mapping for brain iron: associations with cognition in normal aging. Neurobiol Aging 2015; 36: 925-32.
13. Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 2013; 34: 562-75.
14. Hare D, Ayton S, Bush A, Lei P. A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci 2013; 5: 34.
15. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38: 7609-16.
16. Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K, et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010; 257: 455-62.
17. Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 2012; 62: 1593-9.
18. Lee J, Shmueli K, Kang BT, Yao B, Fukunaga M, van Gelderen P, et al. The contribution of myelin to magnetic susceptibility-weighted contrasts in high-field MRI of the brain. Neuroimage 2012; 59: 3967-75.
19. Li W, Avram AV, Wu B, Xiao X, Liu C. Integrated Laplacian-based phase unwrapping and background phase removal for quantitative susceptibility mapping. NMR Biomed 2014; 27: 219-27.
20. Li X, Lei P, Tuo Q, Ayton S, Li QX, Moon S, et al. Enduring elevations of hippocampal amyloid precursor protein and iron are features of beta-amyloid toxicity and are mediated by tau. Neurotherapeutics 2015; 12: 862-73.
21. Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter T, Ames D, et al. Abeta-related memory decline in APOE epsilon4 noncarriers: implications for Alzheimer disease. Neurology 2016; 86: 1635-42.
22. Liu B, Moloney A, Meehan S, Morris K, Thomas SE, Serpell LC, et al. Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem 2011; 286: 4248-56.
23. Lovell MA, Xiong S, Xie C, Davies P, Markesbery WR. Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis 2004; 6: 659-71; discussion 73-81.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.
25. Moon Y, Han SH, Moon WJ. Patterns of brain iron accumulation in vascular dementia and Alzheimer's dementia using quantitative susceptibility mapping imaging. J Alzheimers Dis 2016; 51: 737-45.
26. Pietrzak RH, Lim YY, Ames D, Harrington K, Restrepo C, Martins RN, et al. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers And Lifestyle Flagship study of ageing. Neurobiol Aging 2015; 36: 1231-8.
27. Plascencia-Villa G, Ponce A, Collingwood JF, Arellano-Jimenez MJ, Zhu X, Rogers JT, et al. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer's disease. Sci Rep 2016; 6: 24873.
28. Raven EP, Lu PH, Tishler TA, Heydari P, Bartzokis G. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. J Alzheimers Dis 2013; 37: 127-36.
29. Rival T, Page RM, Chandraratna DS, Sendall TJ, Ryder E, Liu B, et al. Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease. Eur J Neurosci 2009; 29: 1335-47.
30. Rivest-Henault D, Dowson N, Jason PB, Fripp J, Dowling JA. Robust inverse-consistent affine CT-MR registration in MRI-assisted and MRI-alone prostate radiation therapy. Med Image Anal 2015; 23: 56-69.
31. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-83.
32. Salat DH, Greve DN, Pacheco JL, Quinn BT, Helmer KG, Buckner RL, et al. Regional white matter volume differences in nondemented aging and Alzheimer's disease. Neuroimage 2009; 44: 1247-58.
33. Schmidt P, Gaser C, Arsic M, Buck D, Forschler A, Berthele A, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage 2012; 59: 3774-83.
34. Schweser F, Deistung A, Lehr BW, Reichenbach JR. Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: an approach to in vivo brain iron metabolism? Neuroimage 2011; 54: 2789-807.
35. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94: 9866-8.
36. Steiger TK, Weiskopf N, Bunzeck N. Iron level and myelin content in the ventral striatum predict memory performance in the aging brain. J Neurosci 2016; 36: 3552-8.
37. Tahirbegi IB, Pardo WA, Alvira M, Mir M, Samitier J. Amyloid Abeta 42, a promoter of magnetite nanoparticle formation in Alzheimer's disease. Nanotechnology 2016; 27: 465102.
38. Tustison NJ, Avants BB, Cook PA, Zheng YJ, Egan A, Yushkevich PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 2010; 29: 1310-20.
39. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-89.
40. van Bergen JM, Li X, Hua J, Schreiner SJ, Steininger SC, Quevenco FC, et al. Colocalization of cerebral iron with amyloid beta in mild cognitive impairment. Sci Rep 2016; 6: 35514.
41. van Rooden S, Buijs M, van Vliet ME, Versluis MJ, Webb AG, Oleksik AM, et al. Cortical phase changes measured using 7-T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. NMR Biomed 2016; 29: 1289-94.
42. van Rooden S, Versluis MJ, Liem MK, Milles J, Maier AB, Oleksik AM, et al. Cortical phase changes in Alzheimer's disease at 7T MRI: a novel imaging marker. Alzheimers Dement 2014; 10: e19-26.
43. Wang Y, Liu T. Quantitative Susceptibility Mapping (QSM): decoding MRI data for a tissue magnetic biomarker. Magn Reson Med 2015; 73: 82-101.
44. Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, et al. Clinical quantitative susceptibility mapping (QSM): biometal imaging and its emerging roles in patient care. J Magn Reson Imaging 2017. Advance Access published on March 10, 2017, doi: 10.1002/jmri.25693
45. Wu B, Li W, Guidon A, Liu C. Whole brain susceptibility mapping using compressed sensing. Magn Reson Med 2012; 67: 137-47.
46. Yamamoto A, Shin RW, Hasegawa K, Naiki H, Sato H, Yoshimasu F, et al. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J Neurochem 2002; 82: 1137-47.
47. Zhao Y, Raichle ME, Wen J, Benzinger TL, Fagan AM, Hassenstab J, et al. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer disease with magnetic resonance imaging. Neuroimage 2017; 148: 296-304.
48. Zhao Y, Wen J, Cross AH, Yablonskiy DA. On the relationship between cellular and hemodynamic properties of the human brain cortex throughout adult lifespan. Neuroimage 2016; 133: 417-29.